139 related articles for article (PubMed ID: 15075674)
1. Amifostine protection against doxorubicin cardiotoxicity in rats.
Dragojevic-Simic VM; Dobric SL; Bokonjic DR; Vucinic ZM; Sinovec SM; Jacevic VM; Dogovic NP
Anticancer Drugs; 2004 Feb; 15(2):169-78. PubMed ID: 15075674
[TBL] [Abstract][Full Text] [Related]
2. Morphine is protective against doxorubicin-induced cardiotoxicity in rat.
Kelishomi RB; Ejtemaeemehr S; Tavangar SM; Rahimian R; Mobarakeh JI; Dehpour AR
Toxicology; 2008 Jan; 243(1-2):96-104. PubMed ID: 17988779
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of amifostine in protection against doxorubicin-induced acute cardiotoxic effects in rats.
Dragojević-Simić V; Dobrić S; Jaćević V; Bokonjić D; Milosavljević I; Kovacević A; Mikić D
Vojnosanit Pregl; 2013 Jan; 70(1):38-45. PubMed ID: 23401928
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective effect of grape-seed proanthocyanidins on doxorubicin-induced cardiac toxicity in rats.
Ammar el-SM; Said SA; El-Damarawy SL; Suddek GM
Pharm Biol; 2013 Mar; 51(3):339-44. PubMed ID: 23134235
[TBL] [Abstract][Full Text] [Related]
5. Radiopharmaceutical model using 99mTc-MIBI to evaluate amifostine protection against doxorubicin cardiotoxicity in rats.
Yurekli Y; Unak P; Ertay T; Biber Z; Medine I; Teksoz S
Ann Nucl Med; 2005 May; 19(3):197-200. PubMed ID: 15981672
[TBL] [Abstract][Full Text] [Related]
6. Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.
Jahnukainen K; Jahnukainen T; Salmi TT; Svechnikov K; Eksborg S; Söder O
Cancer Res; 2001 Sep; 61(17):6423-7. PubMed ID: 11522636
[TBL] [Abstract][Full Text] [Related]
7. The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat.
Rahimi Balaei M; Momeny M; Babaeikelishomi R; Ejtemaei Mehr S; Tavangar SM; Dehpour AR
Eur J Pharmacol; 2010 Sep; 641(2-3):193-8. PubMed ID: 20534381
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of doxorubicin-induced cardiotoxicity by deferiprone in rats.
Ammar el-SM; Said SA; Suddek GM; El-Damarawy SL
Can J Physiol Pharmacol; 2011 Apr; 89(4):269-76. PubMed ID: 21526973
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of selenium, WR-2721, and their combination in the prevention of adriamycin-induced cardiotoxicity in rats.
Dobrić S; Dragojević-Simić V; Bokonjić D; Milovanović S; Marincić D; Jović P
J Environ Pathol Toxicol Oncol; 1998; 17(3-4):291-9. PubMed ID: 9726805
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Chadwick DP; Ferrans VJ
Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
[TBL] [Abstract][Full Text] [Related]
11. Cardiac autonomic modulation induced by doxorubicin in a rodent model of colorectal cancer and the influence of fullerenol pretreatment.
Potočnik N; Perše M; Cerar A; Injac R; Finderle Ž
PLoS One; 2017; 12(7):e0181632. PubMed ID: 28727839
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotective Effect of Phenytoin on Doxorubicin-induced Cardiac Toxicity in a Rat Model.
Razmaraii N; Babaei H; Mohajjel Nayebi A; Asadnasab G; Ashrafi Helan J; Azarmi Y
J Cardiovasc Pharmacol; 2016 Mar; 67(3):237-45. PubMed ID: 26544684
[TBL] [Abstract][Full Text] [Related]
13. Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
Mohamed HE; Asker ME; Ali SI; el-Fattah TM
J Pharm Pharmacol; 2004 Jun; 56(6):757-68. PubMed ID: 15231041
[TBL] [Abstract][Full Text] [Related]
14. Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy.
Lódi M; Priksz D; Fülöp GÁ; Bódi B; Gyöngyösi A; Nagy L; Kovács Á; Kertész AB; Kocsis J; Édes I; Csanádi Z; Czuriga I; Kisvárday Z; Juhász B; Lekli I; Bai P; Tóth A; Papp Z; Czuriga D
J Transl Med; 2019 Jul; 17(1):229. PubMed ID: 31324258
[TBL] [Abstract][Full Text] [Related]
15. The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
Yeung TK; Jaenke RS; Wilding D; Creighton AM; Hopewell JW
Cancer Chemother Pharmacol; 1992; 30(1):58-64. PubMed ID: 1586981
[TBL] [Abstract][Full Text] [Related]
16. The cardioprotective effects of an antiemetic drug, tropisetron, on cardiomyopathy related to doxorubicin.
Alimoradi H; Barzegar-Fallah A; Hassanzadeh G; Mohammadi-Rick S; Asadi F; Delfan B; Abbasi A; Dehpour AR
Cardiovasc Toxicol; 2012 Dec; 12(4):318-25. PubMed ID: 22744232
[TBL] [Abstract][Full Text] [Related]
17. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529.
Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M
Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601
[TBL] [Abstract][Full Text] [Related]
18. Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model.
Xiang P; Deng HY; Li K; Huang GY; Chen Y; Tu L; Ng PC; Pong NH; Zhao H; Zhang L; Sung RY
Cancer Chemother Pharmacol; 2009 Jan; 63(2):343-9. PubMed ID: 18379782
[TBL] [Abstract][Full Text] [Related]
19. Effects of dexrazoxane and amifostine on evolution of Doxorubicin cardiomyopathy in vivo.
Bjelogrlic SK; Radic J; Radulovic S; Jokanovic M; Jovic V
Exp Biol Med (Maywood); 2007 Dec; 232(11):1414-24. PubMed ID: 18040065
[TBL] [Abstract][Full Text] [Related]
20. Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane.
Della Torre P; Mazué G; Podestà A; Moneta D; Sammartini U; Imondi AR
Cancer Chemother Pharmacol; 1999; 43(2):151-6. PubMed ID: 9923821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
